+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Lyme disease (LD)- Market Insights, Epidemiology and Market Forecast-2027

  • ID: 4702063
  • Drug Pipelines
  • 163 Pages
  • DelveInsight
1 of 4

FEATURED COMPANIES

Lyme disease (LD)- Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Lyme disease (LD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Lyme disease (LD) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Lyme disease (LD) - Disease Understanding and Treatment Algorithm

Lyme disease (LD) is caused by the spirochete Borrelia burgdorferi, injected into the blood stream after an infected tick has been attached 48-72 hrs. It is the most common vector-borne disease. The clinical presentation varies depending on the stage of the illness and includes erthyma migrans, carditis, central nervous system disease, and arthritis. Regardless of the clinical presentation, most patients with Lyme disease (LD) have resolution of their clinical symptoms when treated with appropriate antimicrobials. Persistent symptoms after therapy are most often due to misdiagnosis rather than treatment failure.

It can manifest as early localized disease (erythema migrans), early disseminated disease (e.g meningitis or multiple erythema migrans), or late disease (large joint arthritis). Both the innate and adaptive immune systems contribute to the inflammatory response which results in clinical symptoms. Regardless of the clinical presentation, the vast majority of patients who are treated for Lyme disease (LD) with short courses of appropriate antibiotics do extremely well.

The Lyme disease (LD) market report gives the thorough understanding of the Lyme disease (LD) by including details such as disease definition, disease microbiology, clinical manifestations, risk factors, pathogenesis, and diagnostic trends, prognosis and prevention. It also provides treatment algorithms and treatment guidelines for Lyme disease (LD) in the US, Europe, and Japan.

Lyme disease (LD) Epidemiology

The Lyme disease (LD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 8 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as total incident population of Lyme disease (LD), gender specific incidence of Lyme disease (LD), total diagnosed population of Lyme disease (LD), acute and chronic incidence of Lyme disease (LD) and age specific diagnosed incidence of Lyme disease (LD)] scenario of Lyme disease (LD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to this research, total incident population of Lyme disease (LD) in the 7 major markets is estimated approximately 489,605 cases in 2016 and it is expected to change in 2027.

This research estimates that the Incident population of Lyme disease (LD) will significantly change during the study period [2016-2027].

This research estimates a higher diagnosed incidence of Lyme disease (LD) in the United States with 280,152 diagnosed cases in 2016.

Lyme disease (LD) Drug Chapters

This segment of the Lyme disease (LD) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Currently, the therapeutic options comprises the use of antibiotics for the treatment of Lyme disease (LD). The present market does not holds any approved drug for Lyme disease (LD). The situation is equally crucial for the emerging therapies. The thin pipeline activities in this space makes the situation even more complicated. In the current scenario, the pipeline holds only one active product, VLA15 being developed by Valneva.

Expected Launch of potential therapies (currently only one i.e., VLA15) may increase market size in the coming years, assisted by an increase in diagnosed incident population of Lyme disease (LD). Owing to the positive outcomes during the early stage trials along with the Fast track Designation the only upcoming therapy VLA15 by Valneva has a potential to create a significant positive shift in the Lyme disease (LD) Market Size.

The treatment course for Lyme disease (LD) includes Antibiotics comprising Tetracycline (Doxycycline), Penicillins (Amoxicillin and Benzathine Penicillin), Cephalosporins (Cefuroxime, Ceftriaxone and Cefotaxime), Macrolides (Azithromycin and clarithromycin) and some other medications for the related manifestations associated with the Lyme disease (LD).

The First Line of Treatment for Lyme borreliosis comprises of Tetracycline, Penicillins followed by Cephalosporins.

Lyme disease (LD) Market Outlook

The Lyme disease (LD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to this research, the market of Lyme disease (LD) in 7MM was found to be 403.64 million in 2016, and is expected to increase from 2016-2027.

The United States accounts for the largest market size of Lyme disease (LD) in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Lyme disease (LD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Lyme disease (LD) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Lyme disease (LD) Report Key Strengths
  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake
Lyme disease (LD) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving Lyme disease (LD) market
  • Organize sales and marketing efforts by identifying the best opportunities for Lyme disease (LD) market
  • To understand the future market competition in the Lyme disease (LD) market.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

1. Key Insights

2. Lyme disease (LD) Market Overview at a Glance
2.1. Market Share (%) Distribution of Lyme disease (LD) in 2017
2.2. Market Share (%) Distribution of Lyme disease (LD) in 2027

3. Disease Background and Overview: Lyme disease (LD)
3.1. Introduction
3.2. Microbiology
3.3. Transmission
3.4. Clinical Manifestations
3.4.1. Early Localized Disease
3.4.2. Early Disseminated Disease
3.4.3. Late Disease
3.5. Risk of Lyme disease (LD)
3.6. Pathogenesis
3.7. Diagnosis
3.8. Misdiagnosis
3.9. Differential Diagnosis
3.10. Prognosis
3.10.1. Early Localized Disease
3.10.2. Early disseminated Lyme disease (LD) (< 3 months)
3.11. Post-Treatment Lyme disease (LD) Syndrome (PTLDS)
3.12. Prevention

4. Epidemiology and Patient Population
4.1. Key Findings

5. 7MM
5.1.1. 7MM Total Incident Patient Population of Lyme disease (LD)
5.1.2. 7MM Total Diagnosed Patient Population of Lyme disease (LD)

6. Country Wise-Epidemiology of Lyme disease (LD)
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Incident Population of Lyme disease (LD) in the United States
6.1.3. Gender Specific Incidence of Lyme disease (LD) in the United States
6.1.4. Total Diagnosed Population of Lyme disease (LD) in the United States
6.1.5. Acute and Chronic Incidence of Lyme disease (LD) in the United States
6.1.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in the United States
6.2. EU5 Countries
6.3. Germany
6.3.1. Assumptions and Rationale
6.3.2. Total Incidence of Lyme disease (LD) in Germany
6.3.3. Gender Specific Incidence of Lyme disease (LD) in Germany
6.3.4. Total Diagnosed Population of Lyme disease (LD) in Germany
6.3.5. Acute and Chronic Incidence of Lyme disease (LD) in Germany
6.3.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in Germany
6.4. France
6.4.1. Assumptions and Rationale
6.4.2. Total Incidence of Lyme disease (LD) in France
6.4.3. Gender Specific Incidence of Lyme disease (LD) in France
6.4.4. Total Diagnosed Population of Lyme disease (LD) in France
6.4.5. Acute and Chronic Incidence of Lyme disease (LD) in France
6.4.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in France
6.5. Italy
6.5.1. Assumptions and Rationale
6.5.2. Total Incident Population of Lyme disease (LD) in Italy
6.5.3. Gender Specific Incidence of Lyme disease (LD) in Italy
6.5.4. Total Diagnosed Population of Lyme disease (LD) in Italy
6.5.5. Acute and Chronic Incidence of Lyme disease (LD) in Italy
6.5.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in Italy
6.6. Spain
6.6.1. Assumptions and Rationale
6.6.2. Total Incident Population of Lyme disease (LD) in the United Kingdom
6.6.3. Gender Specific Incidence of Lyme disease (LD) in Spain
6.6.4. Total Diagnosed Population of Lyme disease (LD) in Spain
6.6.5. Acute and Chronic Incidence of Lyme disease (LD) in Spain
6.6.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in Spain
6.7. United Kingdom
6.7.1. Assumptions and Rationale
6.7.2. Total Incident Population of Lyme disease (LD) in the United Kingdom
6.7.3. Gender Specific Incidence of Lyme disease (LD) in the United Kingdom
6.7.4. Total Diagnosed Population of Lyme disease (LD) in the United Kingdom
6.7.5. Acute and Chronic Incidence of Lyme disease (LD) in the United Kingdom
6.7.6. Age Specific Diagnosed Incident Population of Lyme disease (LD) in the United Kingdom
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Incident Population of Lyme disease (LD) in Japan
6.8.3. Gender Specific Incidence of Lyme disease (LD) in Japan
6.8.4. Total Diagnosed Population of Lyme disease (LD) in Japan
6.8.5. Acute and Chronic Incidence of Lyme disease (LD) in Japan
6.8.6. Age Specific Diagnosed Incidence of Lyme disease (LD) in Japan

7. Treatment
7.1. Early localized disease (< 30 days)
7.2. Early disseminated Lyme disease (LD) (< 3 months)
7.3. Late Lyme disease (LD) (> 3 months)

8. United States Guideline on Lyme disease (LD)

9. European Guideline on Lyme disease (LD)
9.1. Adults and Young People (aged 12 and over)
9.2. In Children (Under 12)

10. Unmet Needs

11. Emerging Drugs
11.1. Key Cross Competition
11.2. VLA15: Valneva
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.2.5. Advantages and Disadvantages
11.2.6. Product Profile

12. Lyme disease (LD): 7 Major Market Analysis
12.1. Key Findings
12.2. Market Size of Lyme disease (LD) in 7MM

13. The United States Market Outlook
13.1. United States Market Size
13.2. Total Market size of Lyme disease (LD)
13.3. Market Size by Therapies

14. EU-5 Countries: Market Outlook
14.1. Germany
14.1.1. Total Market size of Lyme disease (LD) in Germany
14.1.2. Market Size by Emerging Therapies
14.2. France
14.2.1. Total Market size of Lyme disease (LD)
14.2.2. Market Size by Emerging Therapies
14.3. Italy
14.3.1. Total Market size of Lyme disease (LD)
14.3.2. Market Size by Emerging Therapies
14.4. Spain
14.4.1. Total Market size of Lyme disease (LD)
14.4.2. Market Size by Emerging Therapies
14.5. United Kingdom
14.5.1. Total Market size of Lyme disease (LD)
14.5.2. Market Size by Emerging Therapies

15. Japan: Market Outlook
15.1. Japan market Size
15.2. Total Market size of Lyme disease (LD)
15.3. Market Size by Emerging Therapies

16. Market Drivers

17. Market Barriers

18. Appendix
18.1. Report Methodology

19. Capabilities

20. Disclaimer

21. About the Publisher

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Valneva
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4702063
Adroll
adroll